Cargando…

Precision oncology for upper GI cancers – Where are we heading?

Detalles Bibliográficos
Autor principal:	Quante, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2021
Materias:	Spotlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695348/ https://www.ncbi.nlm.nih.gov/pubmed/34942535 http://dx.doi.org/10.1016/j.tranon.2021.101319

Ejemplares similares

Precision Medicine in Oncology and Immuno-Oncology: Where We Stand and Where We're Headed
por: Scheuenpflug, Jürgen
Publicado: (2017)

Battery Raw Materials - Where from and Where to?
por: Backhaus, Richard
Publicado: (2021)

Battery Raw Materials - Where from and Where to?
por: Backhaus, Richard
Publicado: (2021)

Editorial: Current innovations in GI-oncology: Where do we stand?
por: Rumpold, Holger, et al.
Publicado: (2022)

Organoids as a tool in drug discovery and patient-specific therapy for head and neck cancer
por: Done, Aaron J., et al.
Publicado: (2023)

Precision medicine in pediatric severe asthma: Targeted blockade of type 2 inflammation
por: Larkin, Allyson S., et al.
Publicado: (2022)

Want to leave the ER? We offer vesicles, tubules, and tunnels
por: Phuyal, Santosh, et al.
Publicado: (2021)

It is a matter of whether we allow microbes to enter the food chain
Publicado: (2022)

Pediatric urologic oncology in the 21(st) century: where we stand and where we’re headed
por: Routh, Jonathan C., et al.
Publicado: (2020)

Where are we now and where are we headed?
por: Langan, Ewan A.
Publicado: (2023)

Cancer Care and the Role of Psychosocial Oncology: Where are We and Where are We Going?
por: Bultz, Barry D.
Publicado: (2016)

Cardiac biomarkers in the field of cardio-oncology
por: Cardinale, Daniela, et al.
Publicado: (2022)

Lifestyle Factors in Cancer Survivorship: Where We Are and Where We Are Headed
por: Vijayvergia, Namrata, et al.
Publicado: (2015)

Harnessing the therapeutic vulnerability of MMR heterogeneity in colorectal cancer
por: Anandappa, Gayathri, et al.
Publicado: (2023)

Animal Sentience: Where are We and Where are We Heading?
por: Proctor, Helen
Publicado: (2012)

Research Integrity: Where We Are and Where We Are Heading
por: Zhaksylyk, Alikhan, et al.
Publicado: (2023)

Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?
por: Jang, Albert, et al.
Publicado: (2021)

Long noncoding RNA amplified in lung cancer rewires cancer pathways
por: Martínez-Terroba, Elena, et al.
Publicado: (2020)

Where are we now and where are we heading in muscle invasive bladder cancer
por: Ku, Ja Hyeon, et al.
Publicado: (2020)

Are we underestimating the richness of visual experience?
por: Haun, Andrew M, et al.
Publicado: (2017)

The double face of cold in cancer
por: Voskarides, Konstantinos
Publicado: (2022)

The ongoing mystery of renal cell cancer
por: Yang, James C.
Publicado: (2021)

Cancer Patients and Risk of Mortality for COVID-19
por: Curigliano, Giuseppe
Publicado: (2020)

Alarming increase of NASH as cause of liver cancer
por: Craciun, Ana, et al.
Publicado: (2022)

Air pollution, EGFR mutation, and cancer initiation
por: Han, Si-Chong, et al.
Publicado: (2023)

PSMA diagnostics and treatments of prostate cancer become mature
por: von Eyben, Finn Edler, et al.
Publicado: (2018)

ARF3 weights the balance for prostate cancer metastasis
por: Caswell, Patrick T.
Publicado: (2023)

When blockchain meets artificial intelligence: An application to cancer histopathology
por: Hong, Runyu, et al.
Publicado: (2022)

Cross communication of diet-microbiome-immune interactions in cancer immunotherapy
por: Zhou, Cheng-Bei, et al.
Publicado: (2022)

Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer?
por: Melief, Cornelis J.M.
Publicado: (2022)

Chromosome-level genome editing uncovers aneuploidy addiction in cancer
por: O’Brien, Siobhan, et al.
Publicado: (2023)

Transition metal ion-doped ferrites nanoparticles for bioimaging and cancer therapy
por: Du, Hui, et al.
Publicado: (2021)

General treatment for metastatic colorectal cancer: From KEYNOTE 177 study
por: Ding, Yuwei, et al.
Publicado: (2021)

Translational Research in the Era of Precision Medicine: Where We Are and Where We Will Go
por: De Maria Marchiano, Ruggero, et al.
Publicado: (2021)

Precision medicine in COPD: where are we and where do we need to go?
por: Sidhaye, Venkataramana K., et al.
Publicado: (2018)

Optimizing hormone therapy for breast cancer: Translating gains to the early-stage setting
por: Chien, A. Jo, et al.
Publicado: (2022)

Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer
por: Makhlin, Igor, et al.
Publicado: (2022)

Why the complications of COVID-19 patients differ in elderly and young cancer patients
por: Bravaccini, Sara, et al.
Publicado: (2022)

Neoadjuvant therapy gains FDA approval in non-small cell lung cancer
por: Leal, Ticiana A., et al.
Publicado: (2022)

CD8(+) T cells: An ineffective armor against prolonged COVID-19 in cancer patients
por: Van Oekelen, Oliver, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_24lebgm851ljlt853l92p9aih1